Company: EDSA
Filing Date: 2025-09-09
Form Type: 424B5
Source: 0001171843-25-005799
Chunk: 42

Company: Edesa Biotech, Inc.
Filing Date: 2025-09-09
Form: 424B5
Chunk 42
---
 benefits, effectiveness and safety of our product candidates; |

| · | the timing or likelihood of regulatory filings and approvals; |

| · | changes in our strategy or development plans; |

| · | the volatility of our common share price; |

| · | the rate and degree of market acceptance and clinical utility of any future products; |

| · | the effect of competition; |

| · | our ability to protect our intellectual property as well as comply with the terms of license agreements 
 with third parties;                                                                                     |

| · | our ability to comply with the continued listing requirements of the Nasdaq Capital Market; |

| · | our ability to identify, develop and commercialize additional products or product candidates; |

| · | reliance on key personnel; |

| · | general changes in economic or business conditions; and |

The
foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein and
in the documents incorporated by reference herein or risk factors that we are faced with that may cause our actual results to differ
from those anticipate in our forward-looking statements. Factors that may affect our results include, but are not limited to, the risks
and uncertainties discussed in the “Risk Factors” section on page 5 of this prospectus, in our Annual Report on Form 10-K
or in other reports we file with the SEC.

Moreover, new risks regularly emerge and it is not possible for our management to predict or articulate all risks we face, nor can we assess the impact of all risks on our business or the extent to which any risk, or combination of risks, may cause actual results to differ from those contained in any forward-looking statements. The Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933 (the “Securities Act”), do not protect any forward-looking statements that we make in connection with this offering. All forward-looking statements included in this prospectus and in the documents incorporated by reference in this prospectus are based on information available to us on the date of this prospectus or the date of the applicable document incorporated by reference. Except to the extent required by applicable laws or rules, we undertake no obligation to publicly update or revise any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future events or otherwise. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the